pharma · Alzheimer Disease · Amyotrophic Lateral Sclerosis · AMLX
Amylyx Pharmaceuticals EMEA
Amylyx Pharmaceuticals EMEA B.V.
Amylyx Pharmaceuticals EMEA is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker AMLX. Primary therapeutic focus areas include Alzheimer Disease, Amyotrophic Lateral Sclerosis, Progres
Cambridge, USA HQ
167 Employees
Public company Type
AMLX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 167
- Programs
- 7
- Drugs
- 2
- Patents
- 9
AMX0035
Phase 3 · small molecule · Amyotrophic Lateral Sclerosis
AMX0035 for Amyotrophic Lateral Sclerosis is a Phase 3 program (small_molecule) at Amylyx Pharmaceuticals EMEA B.V. with 5 ClinicalTrials.gov record(s).
Internal code AMX-3500
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Amylyx Pharmaceuticals EMEA B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Amyotrophic Lateral Sclerosis
- Status
- active
- Trials
- 5